COVERAGE HUB
$JNJ
14 articles in last 30 days
LAST 30 DAYS
14 articles
AVG GRADE
NEUTRAL
score: -0.14
SENTIMENT
BULLISH
TOTAL VIEWS
1
5-DAY GRADE TIMELINE
2026-06-11
TODAY
RECENT COVERAGE · 15 ARTICLES
Johnson & Johnson CEO credits Trump tax policy for $55B US investment push, including $1B in Florida
Johnson & Johnson announced a $55 billion domestic investment commitment, with leadership attributing the decision partly to the...
FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?
This comparative analysis examines two healthcare-focused ETFs—FHLC and IYH—highlighting how structural differences in portfolio...
Salesforce looks to strengthen its AI platform — plus, a positive note for J&J
Salesforce's strategic emphasis on strengthening its AI platform signals competitive positioning within the enterprise software...
Factbox-Global drugmakers invest billions to boost US presence
Global pharmaceutical manufacturers are committing substantial capital to expand their operational footprint across the United States,...
Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained
Johnson & Johnson (JNJ) has demonstrated significant outperformance over recent periods, with year-to-date gains of 15% and a 53%...
How to Build $3,000 a Month in Dividend Income Before You Turn 50
This article presents a personal finance educational piece focused on dividend income strategy rather than market-moving news. The...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech announced Phase 1 clinical proof-of-concept for LB2501, an in vivo dual-targeting CAR-T therapy designed to treat...
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
Johnson & Johnson's TALVEY® bispecific antibody combination has demonstrated clinically meaningful efficacy in the MonumenTAL-3 Phase 3...
Johnson & Johnson (JNJ) to Acquire Firefly Bio for $1B
Johnson & Johnson's $1 billion acquisition of Firefly Bio represents a strategic inorganic growth play in the biotech space, signaling...
Jim Cramer Says He Likes Drug Stocks Here As He Discusses Johnson & Johnson
Jim Cramer's commentary positions pharmaceutical and healthcare equities as a more reliable leadership vector relative to technology...
Jim Cramer Says He Likes Drug Stocks Here As He Discusses Johnson & Johnson
Jim Cramer has signaled renewed confidence in pharmaceutical equities, using Johnson & Johnson (JNJ) as a case study for the sector's...
Johnson & Johnson (JNJ) Jumped on Market Optimism
Johnson & Johnson (JNJ) experienced modest upward momentum amid broader market sentiment, though the underlying catalyst remains...
Is Johnson & Johnson (JNJ) A Good Stock To Buy Now?
Johnson & Johnson (JNJ) is the subject of renewed bullish commentary from dividend-focused investment analysts. The article references a...
Inside ASD: The Story Behind the First Autism ETF
Defiance has launched a specialized autism-focused ETF that integrates autism research and advocacy into its investment thesis,...
7 Best Longevity Stocks to Buy Now
The longevity investment theme reflects structural demographic shifts toward aging populations and increased healthcare spending....
RELATED TICKERS